文献速递肾移植血液净化与透析

依库珠单抗一线治疗移植后血栓性微血管病

"Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.
PubMed 文献 · Kidney Int Rep · 2024-01-10

该回顾性研究纳入45例肾移植后血栓性微血管病(PT-TMA)患者,临床诊断后立即给予依库珠单抗治疗。结果显示治疗2周后血红蛋白和血小板显著升高,肾功能明显改善;6个月时28.8%患者完全恢复,44.4%部分恢复。

要点

  • PT-TMA临床诊断后立即使用依库珠单抗可改善溶血指标和移植肾功能
  • 治疗2周后血红蛋白和血小板显著升高,肾功能明显改善
  • 6个月时28.8%完全恢复、44.4%部分恢复肾功能

核心结论

  • 依库珠单抗治疗与溶血指标正常化及移植肾功能重要且进行性改善相关。

研究设计与样本

  • 回顾性分析45例肾移植后临床诊断PT-TMA并立即接受依库珠单抗治疗的患者临床记录。

主要发现

  • 91.1%患者行肾活检,其中85.4%显示TMA征象;64.4%行补体基因检测。
  • 基因分析发现1个致病性变异、2个意义不确定变异、1个可能良性变异、8个风险多态性和27个风险单倍型。
  • 治疗2周后血红蛋白和血小板显著升高,肾功能明显改善。
  • 治疗6个月后28.8%患者完全肾脏恢复,44.4%部分恢复。

临床怎么用

  • PT-TMA临床诊断后即可考虑立即使用依库珠单抗,无需等待补体基因结果。

局限性

  • 回顾性研究设计,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Posttransplant thrombotic microangiopathy (PT-TMA) is an uncommon event that characterizes approximately 3% to 14% of kidney transplants (KTs), and that is associated with a higher risk of delayed graft function and graft loss. PT-TMA occurs more frequently within the first 3 months after transplant and can be a manifestation of de novo disease or the recurrence of previous atypical hemolytic uremic syndrome (aHUS). Abnormalities in complement regulation genes could explain the increased susceptibility of some patients to PT-TMA. Eculizumab is a humanized monoclonal antibody that inhibits the formation of the membrane attack complex C5b-9. The aim of this study is to evaluate the efficacy of eculizumab as treatment for PT-TMA. METHODS: We retrospectively analyzed clinical records of 45 KT patients who received eculizumab immediately after the clinical diagnosis of PT-TMA. RESULTS: Kidney biopsy was performed in 91.1% of patients, and complement genetic study was performed in 64.4%. Of the kidney biopsies, 85.4% showed signs of TMA; genetic analysis revealed 1 pathogenetic variant, 2 variants of uncertain significance, 1 likely benign variant, 8 risk polymorphisms, and 27 risk haplotypes. After 2 weeks from the treatment starting, hemoglobin and platelets significantly increased. A remarkable improvement in kidney function was also observed. After 6 months, 28.8% of patients had a complete renal recovery whereas 44.4% had a partial recovery. CONCLUSION: This is, to our knowledge, the largest series of KT patients with PT-TMA treated with eculizumab. These data suggest that eculizumab is associated with a normalization of hemolysis indices and an important and progressive improvement of graft function.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Maritati F, Corradetti V, Bini C, et al. "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy. Kidney Int Rep. 2024. PMID: 38765562. doi:10.1016/j.ekir.2024.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。